Stay updated on Pembrolizumab for Recurrent Glioblastoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Recurrent Glioblastoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Recurrent Glioblastoma Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The site footer revision label changed from v3.7.2 to v3.8.0 while the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T18:42:19.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    A sitewide notice about NIH’s terminology transition appeared, and the site revision changed from v3.7.1 to v3.7.2. The study page itself continues to show a 403 error.
    Difference
    1%
    Check dated 2026-10-20T19:15:57.000Z thumbnail image
  4. Check
    31 days ago
    Change Detected
    Summary
    The footer’s site revision changed from v3.7.0 to v3.7.1, while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-06T20:37:06.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, blocking access to the study record. This change represents an access restriction rather than modification of the study content visible on the page.
    Difference
    19%
    Check dated 2026-09-22T23:51:40.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.6 to v3.7.0, indicating a new release of the site's rendering/template. This change is a backend/version update and does not alter the displayed study details or other content.
    Difference
    0.1%
    Check dated 2026-09-15T22:24:30.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    New update timestamps for 2026 were added and older 2025 timestamps were removed in the Study Record Dates, reflecting routine record maintenance rather than changes to study design or results.
    Difference
    0.2%
    Check dated 2026-09-08T18:27:08.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Recurrent Glioblastoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Recurrent Glioblastoma Clinical Trial page.